The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL OMB Number: Estimated average burden hours per response:

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001434316			X Corporation
Name of Issuer			Limited Partnership
FATE THERAPEUTICS INC			
Jurisdiction of Incorporation/Org	ganization		Limited Liability Company
DELAWARE .			General Partnership
Year of Incorporation/Organizat	ion		Business Trust
Over Five Years Ago			Other (Specify)
X Within Last Five Years (Spe	acify Vear) 2007		_
Yet to Be Formed	cony reary 2007		
Tet to be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
FATE THERAPEUTICS INC			
Street Address 1		Street Address 2	
3535 GENERAL ATOMICS COU	RT	SUITE 200	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO	CALIFORNIA	92121	858.875.1803
3. Related Persons			
Last Name	First Name		Middle Name
Wolchko	Scott		
Street Address 1	Street Address 2		
c/o Fate Therapeutics Inc.	3535 General Atom	ics Court, Suite 200	
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92121
Relationship: X Executive Offi	cer Director Promoter		
Clarification of Response (if Neo	cessary):		
Last Name	First Name		Middle Name
Mendlein	John		
Street Address 1	Street Address 2		
c/o Fate Therapeutics Inc.	3535 General Atom	ics Court, Suite 200	
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92121
Relationship: X Executive Offi	cer X Director Promoter		
Clarification of Response (if Neo	cessary):		
Last Name	First Name		Middle Name
Nashat	Amir		
Street Address 1	Street Address 2		
c/o Polaris Venture Management		Suite 3350	

City	State/Province/Country	ZIP/PostalCode	
Waltham	MASSACHUSETTS	02451	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces	sary):		
Last Name	First Name	Middle Name	
Weissman	Carl		
Street Address 1	Street Address 2		
c/o OVP Venture Partners	1010 Market Street		
City	State/Province/Country	ZIP/PostalCode	
Kirkland	WASHINGTON	98033	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Roberts	Bryan	E.	
Street Address 1	Street Address 2		
c/o Venrock Associates	3340 Hillview Avenue		
City	State/Province/Country	ZIP/PostalCode	
Palo Alto	CALIFORNIA	94304	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name	Middle Name	
Nelsen	Robert	T.	
Street Address 1	Street Address 2		
c/o ARCH Venture Partners	8725 West Higgins Road, Suite 290		
City	State/Province/Country	ZIP/PostalCode	
Chicago	ILLINOIS	60631	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces	sary):		
Last Name	First Name	Middle Name	
Shoemaker	Daniel		
Street Address 1	Street Address 2		
c/o Fate Therapeutics Inc.	3535 General Atomics Court, Suite 200		
City	State/Province/Country	ZIP/PostalCode	
La Jolla	CALIFORNIA	92121	
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	sary):		
4. Industry Group			
T. Industry Group			

Health Care Retailing	
X Biotechnology Restaurants	
Health Insurance	
Allines & Alipoits	
Commercial Lodging & Conventions	
Construction Tourism & Travel Services	
REITS & Finance Other Travel	
Residential	
<u> </u>	
Aggregate Net Asset Value Range	
Aggregate Net Asset Value Range No Aggregate Net Asset Value	
No Aggregate Net Asset Value	
No Aggregate Net Asset Value \$1 - \$5,000,000	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable med (select all that apply) Rule 505	_
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Rule 505 Rule 506	_
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Rule 505 X Rule 506 Securities Act Section 4(5)	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9)	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$25,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Not Applicable Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10)	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Net Section 4(5) Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11)	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Decline to Disclose Not Applicable Not Applicable Not Applicable Not Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(12) Section 3(c)(12)	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Not Applicable Net Section 4(5) Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11)	
No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 \$50,000,001 - \$100,000,000 Decline to Disclose Not Applicable Not Applicable Not Applicable Not Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(12) Section 3(c)(12)	
	Restaurants Restaurants Technology Restaurants Technology Computers Computers Other Health Care Other Technology Travel Real Estate Airlines & Airports Commercial Lodging & Conventions Construction Tourism & Travel Services REITS & Finance Other Travel

7. Type of Filing		
7. Type of Filling		
New Notice Date of First Sale 2009-11-10 First Sale Yet to X Amendment	o Occur	
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
X Equity	Pooled Investment Fund Interests	
Debt	Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or O Right to Acquire Security	Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combina merger, acquisition or exchange offer?	tion transaction, such as a Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number X None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbb{X}}$ None	
Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$35,988,360 USD or Indefinite		
Total Amount Sold \$35,988,360 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to enter the number of such non-accredited investors who alread		
Regardless of whether securities in the offering have been or r investors, enter the total number of investors who already hav	may be sold to persons who do not qualify as accredited	18
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders estimate and check the box next to the amount.	fees expenses, if any. If the amount of an expenditure is no	ot known, provide an
Sales Commissions \$0 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		

Provide the amount of the gross	proceeds of the offering	g that has been or is propo	osed to be used for payment	s to any of the person	s required to
be named as executive officers,	directors or promoters	in response to Item 3 above	ve. If the amount is unknown	n, provide an estimate	and check the
box next to the amount.					

	\$0 USD Estimate
onse (if Neces	ssary):

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

Clarification of Resp

Signature and Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
FATE THERAPEUTICS INC	/s/ Scott Wolchko	Scott Wolchko	Chief Financial Officer	2011-04-18

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.